- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03154099
Critical Illness Related Corticosteroids Insufficiency
January 23, 2018 updated by: Fatma mohammad, Assiut University
Critical Illness Related Corticosteroid Insufficiency
the detrimental impact of dysfunction is well recognized.
CIRCI may be characterized by any of the following findings with delayed weaning from mechanical ventilation and hypotension refractory to fluids and vasopressors being most common Hypotension Unresponsiveness to catecholamine infusions Ventilator dependence Abdominal or flank pain High fever with negative cultures and unresponsive to antibiotic therapy Unexplained mental changes (i.e., apathy or depression) Electrolyte abnormalities (hypoglycemia, hyponatremia, hyperkalemia) Neutropenia, eosinophilia
Study Overview
Status
Unknown
Detailed Description
Critically ill patients are at risk for the development of Critical Illness-Related Corticosteroid Insufficiency (CIRCI).
This may present as hypotension, unresponsiveness to catecholamine infusions, and/or ventilator dependence.
Such patients may benefit from administration of exogenous steroids to restore their hemodynamic stability.
Cortisol is vitally important to the maintenance of vascular tone, endothelial integrity, vascular permeability, and total body water distribution.
It also potentiates the vasoconstrictor actions of both endogenous and exogenous catecholamines.
Appropriate activation of the hypothalamic-pituitary-adrenal (HPA) axis in the critically ill patient is essential to stress adaptation and maintenance of homeostasis.
Common causes of adrenal insufficiency in the critical care setting include infection, systemic inflammation, previous glucocorticoid use, and sepsis .
Adrenal insufficiency among critically ill patients is also known as relative adrenal insufficiency; there is either insufficient cortisol or a cortisol level that may be high in absolute terms but insufficient to respond to the degree of stress.
Thus, serum cortisol concentrations that are normal in well patients may be inappropriately low in severely sick patients.
This inability to mount the appropriate response increases the risk of death during severe illness.
While the incidence of CIRCI in the critically ill has been under appreciated, the detrimental impact of such dysfunction is well recognized.
CIRCI may be characterized by any of the following findings with delayed weaning from mechanical ventilation and hypotension refractory to fluids and vasopressors being most common Hypotension Unresponsiveness to catecholamine infusions Ventilator dependence Abdominal or flank pain High fever with negative cultures and unresponsive to antibiotic therapy Unexplained mental changes (i.e., apathy or depression) Electrolyte abnormalities (hypoglycemia, hyponatremia, hyperkalemia) Neutropenia, eosinophilia Diagnostic criteria for CIRCI in the critically ill are not well established, but evidence suggests that modifications from standard testing are warranted.
Random serum cortisol levels, free cortisol, and delta cortisol (change in baseline cortisol at 60 minutes after ACTH stimulation using 250 mcg cosyntropin) are all ways to evaluate for CIRCI.
Study Type
Observational
Enrollment (Anticipated)
30
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
We will recruit all critically ill patients >18 years in Critical Care Unit with APACHE II score >25 then we mesure Random serum cortisol levels and delta cortisol (change in baseline cortisol at 60 minutes after ACTH stimulation using 250 mcg cosyntropin) are all ways to evaluate for CIRCI
Description
Inclusion Criteria:
- We will recruit all critically ill patients in Critical Care Unit with APACHE II score >25.
Exclusion Criteria:
- A known patient with adrenal insufficiency.
- Patient with a previous history of steroid therapy for more than one month.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Critical illness related corticosteroid insufficiency
Time Frame: one year
|
Prevalence of CIRCI .
most common presentations of CIRCI .
the best method of replacment we mesure Random serum cortisol levels and delta cortisol (change in baseline cortisol at 60 minutes after ACTH stimulation using 250 mcg cosyntropin) are all ways to evaluate for CIRCI.
|
one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
February 1, 2018
Primary Completion (ANTICIPATED)
February 1, 2019
Study Completion (ANTICIPATED)
March 1, 2019
Study Registration Dates
First Submitted
May 12, 2017
First Submitted That Met QC Criteria
May 12, 2017
First Posted (ACTUAL)
May 16, 2017
Study Record Updates
Last Update Posted (ACTUAL)
January 25, 2018
Last Update Submitted That Met QC Criteria
January 23, 2018
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- assiut univeristy13577
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Prevalence of CIRCI .
most common presentations of CIRCI .
the best method of replacment
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevalence of CIRCI . Most Common Presentations of CIRCI . the Best Method of Replacment
-
Assiut UniversityNot yet recruitingFigure Out the Best Method of Fixation for Management of Patients With Diabetic Fracture AnkleEgypt